June 25, 2020 -- Catalent will collaborate with Moderna for large-scale commercial fill-finish manufacturing of Moderna's messenger RNA (mRNA)-based COVID-19 vaccine candidate, mRNA-1273, at Catalent's biologics facility in Bloomington, IN.

Under the agreement, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for around-the-clock manufacturing operations to support the production of an initial 100 million doses of the vaccine candidate. The Bloomington biologics facility will provide vial filling using barrier isolator technology within the 875,000-sq-ft space. Production of these doses are intended to supply the U.S. market starting in the third quarter of 2020.

Catalent will also provide clinical supply services from its facilities in Philadelphia, PA. This includes packaging and labeling, storage, and distribution services to support Moderna's phase III clinical trial.